RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses...

Related Keywords

United States ,Tel Aviv ,Israel ,American ,Opregen Clinicaltrials ,Brian Culley ,Adiel Barak ,Roche Group ,Lineage Cell Therapeutics Inc ,Exchange Commission ,Tel Aviv Medical Center ,Genentech ,Lineage Cell Therapeutics ,Vitreoretinal Unit Director ,European Retina ,Vitreous Society ,Winter Meeting ,Cell Therapeutics ,Annual Report ,Markets ,